Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: stable financial guidance with flat to slightly declining revenue and margins, countered by optimistic long-term guidance and strategic divestitures. The Q&A section reveals management's confidence in future demand and strategic initiatives, yet there are uncertainties like DSA demand volatility and unclear expansion details. The positive aspects are balanced by cautious market conditions and flat short-term performance, leading to a neutral sentiment.
Key Financial Performance
Fourth Quarter Revenue $994.2 million, a 2.6% decline on an organic basis from the previous year. Reasons: Revenue declines in all three business segments.
Full Year Revenue $4.02 billion, a 1.6% organic revenue decrease. Reasons: Primarily driven by lower revenue in the DSA and manufacturing segments.
Operating Margin (Fourth Quarter) 18.1%, a decrease of 180 basis points year-over-year. Reasons: Lower revenue, higher staffing and NHP sourcing costs in the DSA segment, and timing of NHP shipments in the RMS segment.
Operating Margin (Full Year) 19.8%, a decline of 10 basis points. Reasons: Cost savings from restructuring and efficiency initiatives helped to protect the margin.
Earnings Per Share (Fourth Quarter) $2.39, a decrease of 10.2% from $2.66 in the fourth quarter of 2024. Reasons: Lower operating margin and a higher tax rate.
Earnings Per Share (Full Year) $10.28, nearly flat compared to $10.32 in 2024. Reasons: Lower revenue offset by cost-saving initiatives.
DSA Revenue (Fourth Quarter) $591.6 million, a decrease of 3.3% on an organic basis. Reasons: Lower study volume, particularly for Discovery Services, while DSA pricing and mix were stable.
DSA Revenue (Full Year) Decreased 2.6% on an organic basis. Reasons: Client demand and higher NHP study starts.
DSA Operating Margin (Fourth Quarter) 20.1%, a 460 basis point decrease from the fourth quarter of 2024. Reasons: Lower revenue, higher NHP sourcing costs, and study starts.
DSA Operating Margin (Full Year) 24.2%, a 150 basis point decline year-over-year. Reasons: Lower revenue and higher costs related to NHP sourcing and staffing.
RMS Revenue (Fourth Quarter) $206.3 million, a decrease of 0.9% on an organic basis. Reasons: Lower NHP revenue and lower sales volume from small models in North America.
RMS Revenue (Full Year) Increased 1.2% on an organic basis. Reasons: Growth in China and favorable pricing offsetting volume declines in North America and Europe.
RMS Operating Margin (Fourth Quarter) 21.9%, a decrease of 90 basis points year-over-year. Reasons: Lower revenue for small models in North America and unfavorable revenue mix due to NHP shipments.
RMS Operating Margin (Full Year) 24.8%, an increase of 110 basis points. Reasons: Favorable mix related to higher NHP revenue and cost savings from restructuring initiatives.
Manufacturing Solutions Revenue (Fourth Quarter) $196.4 million, a decrease of 2.1% on an organic basis. Reasons: Lower CDMO revenue due to the loss of a commercial cell therapy client.
Manufacturing Solutions Revenue (Full Year) Declined 1.6% organically. Reasons: Loss of a commercial cell therapy client and lower year-end plant ordering patterns.
Manufacturing Operating Margin (Fourth Quarter) 32.1%, an increase of 340 basis points. Reasons: Solid performance from Microbial Solutions and restructuring actions.
Manufacturing Operating Margin (Full Year) 28.8%, an increase of 140 basis points. Reasons: Improved performance in Microbial Solutions and cost savings in the CDMO business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NAMs capabilities: Continued to build portfolio in areas relevant to clients, including Retrogenix cell microarray platform, virtual control groups for safety assessment, and PathoQuest's next-gen sequencing platform.
Acquisitions: Acquired K.F. (Cambodia) and PathoQuest to strengthen DSA supply chain and enhance biologics testing capabilities.
Biotech funding environment: Reinvigorated funding environment in the second half of 2025, with a record $28 billion in the fourth quarter.
DSA demand trends: Improved DSA net book-to-bill ratio to 1.1x in Q4 2025, driven by biotech clients.
Cost savings: Generated over $300 million in cumulative cost savings over the last three years through restructuring and efficiency initiatives.
NHP sourcing costs: Acquisition of K.F. expected to normalize NHP sourcing costs and improve operating margins in 2026.
Divestitures: Plan to divest businesses totaling approximately 7% of 2025 annual revenue by mid-2026, expected to result in $0.30 EPS accretion on an annualized basis.
Leadership transition: Jim Foster retiring as CEO in May 2026, with Birgit Girshick taking over as the new CEO.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Biotech Funding Environment: The biotech funding environment slowed in the first half of 2025, leading to softer demand trends from small and midsized biotech clients during the summer months. Although funding improved in the second half, the environment remains uncertain, which could impact future demand.
NHP Sourcing Costs: Higher-than-expected demand for NHP studies led to increased sourcing costs in the fourth quarter of 2025 and is expected to continue into the first quarter of 2026. While costs are expected to normalize later in the year, this remains a short-term financial challenge.
DSA Revenue Decline: DSA revenue decreased by 2.6% on an organic basis in 2025 due to lower study volumes, particularly for Discovery Services. This decline, coupled with higher costs, has pressured operating margins.
RMS Revenue Challenges: RMS revenue faced headwinds from lower NHP revenue due to shipment timing and reduced sales volume of small models in North America. Additionally, CRADL occupancy levels remain constrained due to subdued demand from early-stage biotech clients.
Manufacturing Segment Revenue Decline: The Manufacturing Solutions segment experienced a 1.6% organic revenue decline in 2025, driven by the loss of a commercial cell therapy client and lower year-end ordering patterns in Microbial Solutions.
Operating Margin Pressure: The operating margin decreased in 2025 due to lower revenue, higher staffing costs, and increased NHP sourcing costs. These pressures are expected to persist in the first quarter of 2026.
Regulatory and Client-Specific Challenges: The Biologics Testing business faced challenges in 2025 due to project delays and regulatory hurdles, which impacted sample volumes from several large clients.
CRADL Occupancy Constraints: Occupancy levels for CRADL sites remain pressured by the subdued early-stage biotech market environment, limiting revenue growth potential in this area.
NAMs Adoption Challenges: While NAMs (New Approach Methodologies) and AI have potential, challenges with data availability and proof of concept remain, making this a gradual, long-term evolution rather than an immediate solution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Revenue Growth: Expected to range from down 1% to at least flat in 2026 compared to a 1.6% decline in 2025.
Operating Margin: Expected to improve by 20 to 50 basis points from 19.8% in 2025, driven by the acquisition of K.F. (Cambodia).
Non-GAAP Earnings Per Share: Projected to range from $10.70 to $11.20, representing growth of approximately 4% to 9%.
RMS Revenue: Expected to decline at a low to mid-single digit on an organic basis in 2026, primarily due to lower NHP revenue and CRADL occupancy levels.
DSA Revenue: Expected to range between slightly positive and a low single-digit decrease on an organic basis in 2026, with a return to organic revenue growth anticipated in the second half of the year.
Manufacturing Solutions Revenue: Expected to rebound to a low single-digit increase in 2026, driven by the anniversary of the loss of a commercial cell therapy client and improved performance in Biologics Testing.
Cost Savings: Expected to generate at least $100 million in incremental cost savings above the 2025 level, contributing to margin protection and operational efficiency.
Capital Expenditures: Projected to be approximately $200 million in 2026, representing about 5% of total revenue and a slight reduction from 2025 levels.
Free Cash Flow: Expected to range between $375 million and $400 million in 2026, reflecting higher performance-based cash bonus payments and deferred compensation payments.
Tax Rate: Non-GAAP tax rate for 2026 is expected to be in the range of 22% to 23%, a decrease from 24.6% in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Earnings per share (EPS): Earnings per share were $2.39 in the fourth quarter, a decrease of 10.2% from $2.66 in the fourth quarter of 2024. For 2025, earnings per share were nearly flat at $10.28 compared to $10.32 in 2024.
Share count impact: Below-the-line items largely netted out with the higher tax rate in 2025, primarily offset by lower interest expense and a lower share count and stock repurchases earlier in the year.
Stock repurchases: Stock repurchases earlier in the year contributed to a lower share count in 2025.
Capital deployment: For 2026, the company intends to focus more on debt repayment and maintaining dry powder as it evaluates potential M&A opportunities. Stock repurchases will continue to be evaluated regularly, but the average diluted share count is expected to be slightly higher in 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the dynamics between RMS and DSA regarding NHPs, including the drivers of higher sourcing costs?
A:RMS volumes in Q4 were impacted by timing, with shipments shifting and Q4 being lighter than the previous year. For DSA, higher sourcing costs in Q4 were due to more NHP studies than expected in 2025 and early 2026, requiring purchases from the open market at higher prices. The disconnect arises from having two sources (Asian and Mauritius) and timing issues between internal farm availability and open market needs.
Q:What are your thoughts on NHP utilization for 2026 compared to 2025?
A:It is too early to provide specific thoughts for 2026. However, for 2025 compared to 2024, there is higher demand for NHP studies, driven by a mix of factors and the importance of this research model, which led to the K.F. acquisition to secure the supply chain.
Q:Can you discuss your hiring needs and capacity utilization for DSA as demand ramps up?
A:Physical capacity is in good shape, with facilities not yet optimally utilized. Headcount has been aligned with demand and revenue, with incremental hires in lab sciences and vacant positions filled in 2025. Direct labor will be added a quarter before needed to allow for training, ensuring no drag on operating margins.
Q:How do you view the impact of AI on your business, particularly in wet lab work?
A:AI is seen as an enabling technology rather than a disruptor. It complements work over the long term and is not an immediate threat. AI and NAMs are in early stages, with potential benefits in discovery but limited impact in safety. Charles River is embracing alternative technologies strategically and sees AI as augmentative rather than replacing wet lab work.
Q:Can you provide context on DSA cancellations in the quarter and their distribution?
A:Cancellations and slippage are normal elements of the business. They are back to expected levels, with penalties for insufficient notice covering costs. The distribution of cancellations due to client funding, clinical, and competitive reasons was in line with expectations. The backlog allows for managing cancellations effectively.
Q:What is the current demand environment and urgency of clients compared to last year?
A:Demand is improving due to factors like biotech funding and pharma companies stabilizing their portfolios. The environment feels more stable, with global biopharma increasing candidate numbers and small/mid-sized biotech showing more positivity. Growth is expected in the second half of the year.
Q:How should we model margin improvement throughout the year?
A:Sequential improvement in operating margin will be driven by cost savings, lower sourcing costs due to the K.F. acquisition, and improving demand. Q1 will face headwinds from stock compensation and NHP timing, but margins are expected to improve throughout the year.
Q:What is the demand environment in China, particularly for RMS?
A:The China business, focused on RMS, continues to perform well. China is becoming a more sophisticated and innovative market, with potential for expanding services beyond RMS in the future.
Q:What is the outlook for biologics in 2026?
A:Biologics returned to growth in Q4 2025 due to higher demand, particularly from Europe. Challenges from 2025, such as lower sample volumes and regulatory delays, are behind, and the business is expected to grow in 2026.
Q:What caused the volatility in DSA demand in 2025, and what gives confidence for 2026?
A:Volatility in 2025 was due to soft demand from clients, concerns about biotech funding, and pharma companies facing a patent cliff. Confidence for 2026 comes from improved biotech funding, a strong Q4 2025 book-to-bill ratio, and a more stable demand environment.
Q:What is the status of the divestiture process, and how will proceeds be used?
A:The divestiture process is ongoing, with expected closure in the first half of 2026. Proceeds will be allocated based on market conditions, potentially for M&A, debt repayment, or share repurchases.
Q:What is the long-term outlook for NHP sourcing costs with the K.F. acquisition?
A:The K.F. acquisition solidifies the NHP supply chain, reducing reliance on the open market. Savings will compound over time, with $0.25 benefit in 2026 and $0.60 accretion expected by 2027.
Q:How are clients using NAMs, and what is the adoption level?
A:NAMs are used across a broad client base, with big pharma leading adoption. They are more pronounced in discovery and are seen as augmentative rather than replacing wet lab work. Charles River is investing in NAMs strategically.
Q:How would increased AI-driven target screening impact your business?
A:Increased AI-driven target screening could accelerate lead compound identification, benefiting clients and potentially increasing demand for Charles River's services. It would likely result in more molecules moving through preclinical and clinical stages.
Q:What is the update on capital deployment priorities?
A:Capital deployment priorities include maintaining leverage below 3 turns, focusing on M&A in areas like bioanalysis, and considering share buybacks or debt repayment based on market conditions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the percentage or dollar amount of DSA cancellations, citing that they do not disclose such figures. Additionally, they did not provide a clear timeline or specifics on potential expansions in China beyond RMS, stating it is too early to predict.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO
CFO
Chief
DSA
Interim
KF PathoQuest
KF acquisition
NAMs
NHP study
North America
Officer
PathoQuest acquisition
RMS
River
Vice President
action
approach
basis point
benefit
biopharma
booking
client
compensation
cost saving
debt
demand trend
drug
efficiency
experience
factor
headwind
industry
leader
margin basis
model
opportunity
science
segment
shipment
stock
timing
volume
CRL Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neutral6-2
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary reveals solid financial performance, optimistic guidance, and strategic initiatives that indicate potential growth. The Q&A section highlights positive trends such as increased proposal volumes, AI's potential in drug discovery, and improving margins. Although there are some uncertainties, like the sluggish demand from smaller biotechs, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and strategic focus on M&A and capital allocation. Despite the lack of market cap data, these factors suggest a likely positive stock price movement in the short term.
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
CRL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
